226 related articles for article (PubMed ID: 25127034)
1. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
3. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
[TBL] [Abstract][Full Text] [Related]
5. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
6. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
8. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
[TBL] [Abstract][Full Text] [Related]
9. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.
Lee LM; Cao J; Deng H; Chen P; Gatalica Z; Wang ZY
Anticancer Res; 2008; 28(1B):479-83. PubMed ID: 18383888
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
11. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
12. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
13. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
14. Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.
Zheng Y; Zhang J; Xu ZZ; Sheng JM; Zhang XC; Wang HH; Teng XD; Liu XJ; Cao J; Teng LS
J Zhejiang Univ Sci B; 2010 Feb; 11(2):144-50. PubMed ID: 20104649
[TBL] [Abstract][Full Text] [Related]
15. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.
Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9063-8. PubMed ID: 16754886
[TBL] [Abstract][Full Text] [Related]
16. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
17. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
18. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer.
Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG
Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373
[TBL] [Abstract][Full Text] [Related]
19. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
Zhang J; Li G; Li Z; Yu X; Zheng Y; Jin K; Wang H; Gong Y; Sun X; Teng X; Cao J; Teng L
Steroids; 2012 May; 77(6):666-73. PubMed ID: 22402113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
